Menu

Close

Sign InSign Out

Materials

Co-pay Cards & Patient Savings Offers

Request Samples

Hospital Products

Vaccines, Biologics & ​​​​​​​Small-molecule Medicines

Pfizer Oncology Together

Pfizer RxPathways

Events

Materials

Videos

Menu

Close

Efficacy

Phase III Study Primary Endpoints

Success in ISGA: Clear or ​​​​​​​almost clear

Study Design

Phase III Study Secondary Endpoints

ISGA clear or almost clear

Time to ISGA success

Phase III Study: Other Endpoints

Pruritus

Quality of life assessments

Infant Study: Exploratory efficacy Endpoints

ISGA clear or almost clear

%BSA, EASI & POEM

Safety Data

Phase III Study Adverse Reactions*

Pivotal trial & 48-week extension study
Adverse Reactions

Open-Label Safety Extension Study*

Open-Label Safety Extension Study Rescue ​​​​​​​Therapy Endpoint

Study design

Infant Safety Study**

Adverse Reactions

Study design and Demographics

Savings & Support

Events

Materials

Videos

Copay Cards

Cost and Coverage

  • Prescribing Information
  • Patient Information
  • Patient Site
  • EUCRISA Efficacy

    Steroid-Free EUCRISA has proven efficacy in patients ≥ 2 years

    Overview About ISGA Baseline Characteristics

    EUCRISA was studied across a spectrum of patients

    EUCRISA baseline characteristics in pivotal trials2

    TRIAL 1 AND TRIAL 2 POOLEDa

    Crisaborole, 2%
    (n=1016)

    Vehicle (n=506)

    TRIAL 1 AND TRIAL 2 POOLEDa

    Crisaborole, 2%
    (n=1016)

    Vehicle (n=506)

    Age (years)

    Mean (SD)

    12.3 (12.16)

    12.1 (11.65)

    Median

    9.0

    9.0

    Min to max

    2 to 79

    2 to 79

    2-11 years

    627 (61.7%)

    315 (62.3%)

    • 2-6 years

    335 (33.0%)

    171 (33.8%)

    • 7-11 years

    292 (28.7%)

    144 (28.5%)

    12-17 years

    247 (24.3%)

    124 (24.5%)

    >18 years

    142 (14.0%)

    67 (13.2%)

    Mean (SD)

    12.3 (12.16)

    12.1 (11.65)

    Median

    9.0

    9.0

    Min to max

    2 to 79

    2 to 79

    2-11 years

    627 (61.7%)

    315 (62.3%)

    • 2-6 years

    335 (33.0%)

    171 (33.8%)

    • 7-11 years

    292 (28.7%)

    144 (28.5%)

    12-17 years

    247 (24.3%)

    124 (24.5%)

    >18 years

    142 (14.0%)

    67 (13.2%)

    Sex

    Male

    450 (44.3%)

    225 (44.5%)

    Female

    566 (55.7%)

    281 (55.5%)

    Male

    450 (44.3%)

    225 (44.5%)

    Female

    566 (55.7%)

    281 (55.5%)

    Ethnicity

    Not Hispanic or Latino

    816 (80.3%)

    405 (80.0%)

    Hispanic or Latino

    200 (19.7%)

    101 (20%)

    Not Hispanic or Latino

    816 (80.3%)

    405 (80.0%)

    Hispanic or Latino

    200 (19.7%)

    101 (20%)

    Race

    White

    617 (60.7%)

    306 (60.5%)

    Black or African American

    285 (28.1%)

    139 (27.5%)

    Asian

    52 (5.1%)

    27 (5.3%)

    Otherb

    44 (4.3%)

    21 (4.2%)

    Native Hawaiian or Pacific Islander

    7 (0.7%)

    8 (1.6%)

    American Indian or Alaska Native

    11 (1.1%)

    5 (1.0%)

    White

    617 (60.7%)

    306 (60.5%)

    Black or African American

    285 (28.1%)

    139 (27.5%)

    Asian

    52 (5.1%)

    27 (5.3%)

    Otherb

    44 (4.3%)

    21 (4.2%)

    Native Hawaiian or Pacific Islander

    7 (0.7%)

    8 (1.6%)

    American Indian or Alaska Native

    11 (1.1%)

    5 (1.0%)

    aTrial 1 and Trial 2 pooled data.
    bIncludes American Indian, Alaska Native, Native Hawaiian, Pacific Islander, or Other.
    ​​​​​​​SD=standard deviation.
    References
    1. ​​​​​​​EUCRISA® (crisaborole) Full Prescribing Information. December 2018.
    2. Data on file. Pfizer Inc., New York, NY.
    3. Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.
    4. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
    5. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.

    Pivotal Trial Primary Efficacy Endpoint

    Find out more about the proportion of patients who achieved clear or almost clear at day 29 in the primary endpoint

    Learn more

    ** This is an optional area where footnotes can live.

    If babies could talk, what would they tell you?

    Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him

    Not an actual patient

    Watch JP's story

    3 to <24 Month Study Data

    Learn more about 28-day, open-label, single-arm, safety study in 3 to <24 month old patients3

    See data

    ** This is an optional area where footnotes can live.

    Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

    The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

    Learn more

    Copay Cards

    *Eligible patients pay as little as $10​​​​​​

    Terms and Conditions apply​​​​​​

    ​​​​* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Download Copay cards

    ** This is an optional area where footnotes can live.

    Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources

    ** This is an optional area where footnotes can live.

    Order Samples

    Register or sign in to check availability and request samples.

    Order now

    ** This is an optional area where footnotes can live.

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.

    Please see full Prescribing Information.

    OK. We'll need you to sign in before we can determine if you are aligned with a sales  representative. 

    If you select 'Yes', you will be required to enter your username and password in the sign-in form  that will appear over this window.  

    Would you like to sign in now?